Keyword
Quick search:
Content Search
Result Content Research
Result Content Research
1 Kymera Therapeutics to Present Pharmacokinetic and
2 Is Kymera Therapeutics, Inc. (NASDAQ:KYMR) Popular Amongst Institutions?
3 Where Kymera Therapeutics Stands With Analysts
4 Kymera's Protein Degraders are Expanding the Druggable Universe
5 Can Kymera Therapeutics Inc (KYMR) Stock Rise to the Top of Healthcare Sector Wednesday?
6 $KYMR Kymera Therapeutics Inc Files For Mixed Shelf Size Not Disclosed
7 Kymera Therapeutics : Departure of Directors or Certain Officers (Form 8-K)
8 Kymera (KYMR) falls 5.09% to Close at $52.77 on October 11
9 Zacks: Analysts Anticipate Kymera Therapeutics, Inc. (NASDAQ:KYMR) Will Post Quarterly Sales of $20.60 Million
10 Kymera (KYMR) falls 1.50% on Moderate Volume September 21
11 Kymera Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
12 Movers & Shakers, Sept. 17 | BioSpace
13 Kymera Therapeutics to Present at Upcoming September Investor Conferences
14 Kymera Therapeutics Announces Second Quarter 2021 Financial
15 Kymera Therapeutics Announces Positive Interim Results from
16 Kymera Therapeutics Appoints Karen Weisbach as Vice President, People and Culture and Jolly Bhatia as Vice President, Quality
17 Kymera Therapeutics Seeks To Raise Capital Via 4M Shares Equity Offering To Fund Oncology Franchises
18 Kymera Therapeutics: Selective Protein Degradation Second Mover To Watch
19 Kymera Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters
20 Kymera Therapeutics Presents New Data Demonstrating Proof-of-Degradation Using Novel Tissue-Restricted E3 Ligase
21 Former Kymera exec gets $30M to launch PAQ Therapeutics, a new degradation-focused startup
22 Immix Biopharma: Tissue-Specific Therapeutics Developer Files For IPO
23 Kymera Therapeutics to Present New Data Demonstrating both
24 Kymera Therapeutics Presents New Preclinical Data for its IRAKIMiD Degrader KT-413 Demonstrating Strong Antitumor Activity
25 Kymera Therapeutics Appoints Elaine Caughey, MBA, as Chief
26 Kymera Therapeutics to Submit IND for STAT3 Degrader in 2021
27 Kymera Therapeutics to Present New Results from Non-Interventional Study in Patients with Hidradenitis Suppurativa at
28 The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
29 Kymera Therapeutics Announces Key 2021 Goals and Milestones
30 Kymera Therapeutics Announces Key Leadership Appointments
31 Analysts Just Shaved Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Forecasts Dramatically
32 Kymera Therapeutics Is A Protein Degrading Pioneer With A Triple-Figure Share Price In Waiting
33 Targeted-protein Degradation Therapeutics Market Regional Outlook, Competitive Strategies And Forecast up to 2026
34 A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO
35 Kymera Therapeutics Announces Third Quarter 2020 Financial
36 Tracking Baker Brothers Portfolio
37 Kymera Therapeutics And Sanofi Enter Into Strategic Partnership To Advance Novel Protein Degrader Therapies To Patients
38 Kymera Therapeutics to Present at the 39th Annual JP
39 Here's What Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shareholder Ownership Structure Looks Like
40 Kymera Therapeutics Unveils IPO Pitch for Protein Degradation
41 Kymera Therapeutics Announces First-in-Human Dose in Phase 1 Trial of KT-474, a First-in-Class IRAK4 Protein Degrader to Treat Immune-Inflammatory Diseases | Small Molecules | News Channels
42 Kymera Therapeutics, fresh off a $2B Sanofi biobucks pact, guns for an IPO
43 Kymera Therapeutics Announces $102 Million Series C Financing to Advance its Protein Degrader Pipeline and Platform
44 Is it Time to Dump Kymera Therapeutics Inc (KYMR) Stock After it Has Fallen 7.92% in a Week?
45 Kymera Therapeutics Appoints Dr. Richard Chesworth as Chief
46 Kymera, raising $173M+, becomes the 48th biotech IPO of the year as 2020 surpasses 2019
47 New Report On Protein Degradation Therapy Market Evolving Technology and Growth Outlook 2021 to 2026
48 Thinking about buying stock in Iterum Therapeutics, Kymera Therapeutics, Senseonics, Avrobio, or ChemoCentryx?
49 Kymera Therapeutics to Relocate From Cambridge to Watertown Biotech Cluster
50 Kymera Therapeutics Announces Pricing of Upsized Initial Public Offering
51 Kymera Therapeutics Appoints Biopharma Veterans Pamela
52 Kymera Therapeutics to Present Interim Results from a Non-Interventional Study Characterizing IRAK4 Expression and Demonstrating
53 Preclinical inflammatory disease biotech Kymera Therapeutics sets terms for $125 million IPO
54 Kymera pens new pact with GSK as protein degradation R&D continues to ramp up
55 Kymera Therapeutics Announces $65 Million Series B Financing to Advance Pipeline of Targeted Protein Degraders in Oncology and Immunology
56 Kymera Therapeutics Announces Series A to Advance Novel Therapeutic Modality and Develop Innovative Therapies
57 Lilly puts more money into protein degradation
58 Kymera Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters' Option
59 Kymera Therapeutics Target of Unusually High Options Trading (NASDAQ:KYMR)
60 Vertex Establishes $70 Million Protein Degradation Partnership with Kymera Therapeutics
61 Kymera Therapeutics is Named one of the FierceBiotech's "Fierce 15" Companies of 2019
62 Kymera Therapeutics to Disclose IRAKIMiD Degrader Program and Present Preclinical Data Demonstrating Potent Immunomodulatory and Antitumor Activity for its Novel STAT3 Degraders in Immuno-oncology
63 Kymera Therapeutics Begins U.S. IPO Effort
64 What is Kymera Therapeutics' IPO Price?
65 Kymera Therapeutics Announces Leadership Transitions
66 Atlas-backed Kymera grabs $102M as its protein degradation technology heads into clinic
67 Kymera Therapeutics (NASDAQ:KYMR) Rating Reiterated by Brookline Capital Management
68 Kymera Therapeutics begins potential $2bn R&D deal with Sanofi
69 IPO Flurry Continues With Aerovate, Acumen and More
70 Ixaka Appoints Laurent Audoly as a Non-Executive Director
71 Dr. Jared Gollob Joins Kymera Therapeutics as Chief Medical Officer
72 Sanofi Pays Kymera $150M to Kick Off Protein Degrader Partnership
73 Monte Rosa snags $95M to speed lead 'molecular glue' treatment into the clinic
74 Kymera tripling HQ with move out of Cambridge
75 Bayer beefs up discovery work with Vividion buyout
76 Biotech Kymera's $174M IPO extends cash runway to 2025
77 Left out of SPAC pack, BioTheryX raises $92M in rare series E to hold over until potential end of year IPO
78 Monte Rosa sticks its Nasdaq landing, banking $222M for 'molecular glues'
79 Expansion raises $80M to develop drugs for neurodegenerative disease
80 Kymera Therapeutics has leadership transitions – PharmaLive
81 Kymera hands the helm to Novartis vet — and founding CSO — Nello Mainolfi
82 4 Trending Biotech Stocks To Watch This Week
83 Money on the Move: June 30 – July 6
84 A Pac-Man offense: Paq Therapeutics closes $30M series A round to harness autophagy for targeted degradation
85 Monte Rosa Therapeutics Strengthens Leadership with Key Executive and Board Appointments
86 Vyant Bio Announces Newly Appointed Board of Directors
87 Sanofi, Kymera Therapeutics ink Strategic Partnership To Advance Novel Protein Degrader Therapies
88 Sanofi kicks off PhII test for RIPK1 inhibitor, triggering Denali milestone; Italian biotech flops key endpoint in muscular dystrophy study
89 Versant Ventures unveils new startup that stabilizes proteins to treat disease
90 AbbVie pays Frontier $55M to pursue hard-to-drug targets
91 Who will follow Curis’s clinical validation?
92 Faze Medicines launches with $81M Series A, Alnylam vet heading science in play at biomolecular condensates
93 Kymera gets $65M in series B as protein degradation nears clinic
94 Addex Therapeutics Starts Mid-Stage Study For Dipraglurant In Parkinson's Associated Dyskinesia
95 Atlas Venture Welcomes Samantha Truex as Venture Partner
96 Novel Rheumatoid Arthritis drugs succeed in the clinical trials
97 Kymera Therapeutics Presents First Validation of IRAK4 Protein Degraders in MYD88-Mutant Lymphoma
98 Kymera CEO Laurent Audoly Departs, Nelllo Mainolfi Named President
99 Clinical Catch-Up: March 1-5
100 Hidradenitis Suppurativa Pipeline Landscape: Novel Emerging